Drug Profile
Research programme: vaccines - Kymab / Bill and Melinda Gates Foundation
Alternative Names: Anti-pertussis toxin - Kymab/Bill & Melinda Gates Foundation; HIV vaccine - Kymab/Bill & Melinda Gates Foundation; Malaria vaccine - Kymab/Bill & Melinda Gates FoundationLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Kymab
- Developer Bill & Melinda Gates Foundation; Kymab
- Class AIDS vaccines; Malaria vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections; Malaria; Pertussis
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in HIV-infections in United Kingdom (Parenteral)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Malaria in United Kingdom (Parenteral)
- 28 Nov 2022 No recent reports of development identified for preclinical development in Pertussis in United Kingdom (Parenteral)